In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

5th Gene Therapy for Neurological Disorders 2023

Nov 06, 2023 - 09:00 AM - Nov 09, 04:00 PM
Hanson Wade Group
Boston Park Plaza
50 Park Plaza,

ZIP: 02116
Phone: +1 617 455 4188

Ticket Price: USD 2999.00 - USD 6395.00


Despite a challenging 2022 for Gene Therapy developers targeting the CNS, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community.

The 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments, overcome delivery challenges, address translational bottlenecks, and create a bulletproof clinical development strategy, to propel the next wave of CNS gene therapies forward.

This summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights.

Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.

Tickets: https://go.evvnt.com/1797350-2?pid=1052 
Brochure: https://go.evvnt.com/1797350-3?pid=1052 

Drug Developer Pricing - Full Access Pass (2 Day Conference + Pre-Conference Workshop Day AND Post-Conference Delivery Day): USD 5195.00,
Drug Developer Pricing - 2 Day Conference + Workshop Day OR Post Conference Delivery Day: USD 4097.00,
Drug Developer Pricing - 2 Day Conference Only: USD 2999.00,
Solution Provider Pricing - Full Access Pass (2 Day Conference + Pre-Conference Workshop Day AND Post-Conference Delivery Day): USD 6395.00,
Solution Provider Pricing - 2 Day Conference + Workshop Day OR Post Conference Delivery Day: USD 5097.00,
Solution Provider Pricing - 2 Day Conference Only: USD 3799.00


Speaker Details

Adam Shaywitz, Chief Medical Officer, Bridge Bioscience Corp, Alfica Sehgal Senior, Vice President and Head of Discovery and Translation Discovery, CAMP4 Therapeutics, Ambreen Sayed-Zahid, Scientist, Voyager Therapeutics, Amy Hicks, Associate Director, Entrada Therapeutics Inc., Anindya Sen, Executive Director, Prevail Therapeutics, Dorota Gruber, Assistant Chief, Pediatric Cardiogenomics, Cohen Children's Medical Center, Dunni Odumosu, Vice President, Global Regulatory Affairs and Sciences, Bridge Bioscience Corp, Edgar Rodriguez-Lebron, Chief Executive Officer and Co-Founder, Lacerta Therapeutics Inc., Eloise Hudry, Associate Director - Cell, Gene Therapy and Preclinical Safety, NIBR, Fergus Quigley, Director - Early Stage Device Development Leader, Takeda Pharmaceutical Co. Ltd., Francesco Lotti, Assistant Professor - Pathology and Cell Biology, Project ALS Therapeutics Core, Frederic Padilla, Director Gene and Cell Therapy Program, Focused Ultrasound Foundation, Gabriele Proetzel, Senior Director - Neuroscience External Research, Takeda Pharmaceutical Co. Ltd., Gregory Stewart, Consultant, Alcyone Life Sciences, Habib Baghirov, Scientific Lead, Roche, Jan Panteli Director, Upstream Process Development and CMC Program Lead, Ultragenyx Pharmaceutical Inc, Jonathan Foley, Scientific Director, ArgoBio Studio, Joseph Glorioso, Professor, University of Pittsburgh, Juan Li, Senior Scientist - Research and Central Nervous System, Spark Therapeutics, Julia Taravella, Executive Director, Rare Trait Hope Fund, Katherine Deng, Senior Principle Scientist, Abbvie, Karen Pignet Founder, Chairman and Chief Executive Officer, Lysogene, Leszek Lisowski, Unit Head Translational Vectorology Research Unit, University of Sydney, Mansuo Shannon, Chief Scientific Officer, Prevail Therapeutics, Manuel Mohr, Director and Head of Vector Engineering, Former Cellinfinity Bio Employee, Manuel Sanchez-Felix, Associate Director, Novartis AG, Mark Richardson, Director of Functional Neurosurgery, Harvard University, Matt Kelley, Senior Scientist, Pfizer, Mengying Zhang, Vector Engineering Scientist, Biogen, Michal Fortuna, National Health Policy and Biodistribution Scientist Lead, Allen Institute, Nick Todd, Assistant Professor, Brigham and Women's Hospital, Ornit Chiba-Falek, Professor and Div Chief, Co-Founder, CLAIRIgene, Pannie Trifillis, Vice President and Head of Global Scientific Affairs,GMA, PTC Therapeutics, Sanjay Chandriani, Director, Maze Therapeutics, Sarah Jacobo, Global Gene Therapy and Vectorology Lead, Takeda Pharmaceutical Co. Ltd., Shyam Ramachandran, Senior Group Head of Neurologic Diseases, Sanofi, Sourav Choudhury, Head of Lab, Sanofi, Stephen Chrzanowski, Child Neurology Resident at Boston Children's Hospital, Boston Children's Hospital, Susan Catalano, Chief Scientific Officer, Capsida Biotherapeutics, Torben Moos, Professor, Aalborg University

Event Categories
Keywords: Health , science , Conferences


Events Calendar

29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 1 2

Event Location


VIP Life Time Subscription to our Newsletters!